transcodetherapeutics.com (RNAZ) EV/EBITDA Multiple
The EV/EBITDA data on GURU.Markets, which stands at 0.00, illustrating the price evolution of the quotes, confirms that TransCode Therapeutics (RNAZ) remains independent of economic cycles and GDP. TransCode Therapeutics (RNAZ) develops anti-cancer agents using unique drug delivery systems to bypass competitors. However, geopolitical fragmentation and the disruption of reagent supply chains create risks for international scientific collaboration.
RNAZ (transcodetherapeutics.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio TransCode Therapeutics, Inc.|RNAZ - Aggregate Debt Obligations|Debt to Book Value TransCode Therapeutics|RNAZ - Amount of Long-Term Liabilities|Company Short-Term Debts TransCode Therapeutics|Quick Ratio transcodetherapeutics.com
- business earnings and investment ratios data:
RNAZ - Company Net Income|Expected Profit TransCode Therapeutics|RNAZ - Company Value to Net Income|Forward P/E Multiple TransCode Therapeutics, Inc.|RNAZ - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics|RNAZ - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) TransCode Therapeutics|RNAZ - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months transcodetherapeutics.com|RNAZ - Earnings growth in current year|Expected earnings per share growth for next year TransCode Therapeutics
Summary company analysis:TransCode (RNAZ)
High risks of RNA therapy trial failures and a capital deficit leave TransCode Therapeutics (RNAZ) vulnerable to financial shocks. The EV/EBITDA multiple compares the total enterprise value with operating profit before depreciation, taxes, and interest, revealing the actual value of assets relative to their ability to generate cash flow. Whether an asset is undervalued or overheated becomes transparent when analyzing the historical EV/EBITDA levels of the company.
Competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|Ionis Pharmaceuticals - EV/EBITDA Multiple|repligen.com (RGEN) - Enterprise Value to EBITDA Ratio|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA CRISPR Therapeutics Inc (CRSP)|WGS (Sema4) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx Corp)|EV/EBITDA Multiple BEAM|SRPT - Company Value to EBITDA|Twist Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TXG|NTLA: Enterprise Value to EBITDA Ratio|Stoke Corp - Enterprise Value to Operating Income Before Depreciation Ratio|BLFS: EV/EBITDA Multiple|wavelifesciences.com - Business Value to Operating Income Before Depreciation|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|TSHA (Taysha Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QURE (uniQure N.V.)|EV/EBITDA Multiple meiragtx.com MGTX|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SLDB|OCGN: EV/EBITDA Multiple|Company Value to EBITDA PacBio Corp (PACB)|Enterprise Value to EBITDA Ratio BNTC|EV/EBITDA Multiple designtx.com|Enterprise Value to EBITDA Ratio RCKT (Rocket Pharmaceuticals, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio FDMT|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Korro Bio Inc. (KRRO)|Editas Medicine, Inc. - EV/EBITDA Multiple|silence-therapeutics.com (SLN) - Enterprise Value to EBITDA Ratio|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CDXS - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sangamo|NAUT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GBIO (Generation Bio)|EV/EBITDA Multiple Boundless Bio Inc. BOLD|XCUR: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio IMNN|PHIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MBIO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple immunoprecise.com (IPA)|Omega Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio OMIC (singulargenomics.com)|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals, Inc (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
